Suzhou Basecare Medical Corporation Limited

SEHK:2170 Stock Report

Market Cap: HK$741.3m

Suzhou Basecare Medical Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Bo Liang

Chief executive officer

CN¥3.0m

Total compensation

CEO salary percentage84.4%
CEO tenure14yrs
CEO ownershipn/a
Management average tenure6.3yrs
Board average tenure2.7yrs

Recent management updates

Here's Why Shareholders May Want To Be Cautious With Increasing Suzhou Basecare Medical Corporation Limited's (HKG:2170) CEO Pay Packet

May 30
Here's Why Shareholders May Want To Be Cautious With Increasing Suzhou Basecare Medical Corporation Limited's (HKG:2170) CEO Pay Packet

Recent updates

Suzhou Basecare Medical (HKG:2170) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Nov 18
Suzhou Basecare Medical (HKG:2170) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Lacklustre Performance Is Driving Suzhou Basecare Medical Corporation Limited's (HKG:2170) Low P/S

Sep 27
Lacklustre Performance Is Driving Suzhou Basecare Medical Corporation Limited's (HKG:2170) Low P/S

Here's Why Shareholders May Want To Be Cautious With Increasing Suzhou Basecare Medical Corporation Limited's (HKG:2170) CEO Pay Packet

May 30
Here's Why Shareholders May Want To Be Cautious With Increasing Suzhou Basecare Medical Corporation Limited's (HKG:2170) CEO Pay Packet

Suzhou Basecare Medical Corporation Limited's (HKG:2170) Shares Leap 27% Yet They're Still Not Telling The Full Story

May 09
Suzhou Basecare Medical Corporation Limited's (HKG:2170) Shares Leap 27% Yet They're Still Not Telling The Full Story

Suzhou Basecare Medical Corporation Limited (HKG:2170) Screens Well But There Might Be A Catch

Mar 22
Suzhou Basecare Medical Corporation Limited (HKG:2170) Screens Well But There Might Be A Catch

Is There An Opportunity With Suzhou Basecare Medical Corporation Limited's (HKG:2170) 47% Undervaluation?

Aug 01
Is There An Opportunity With Suzhou Basecare Medical Corporation Limited's (HKG:2170) 47% Undervaluation?

Lacklustre Performance Is Driving Suzhou Basecare Medical Corporation Limited's (HKG:2170) 27% Price Drop

May 26
Lacklustre Performance Is Driving Suzhou Basecare Medical Corporation Limited's (HKG:2170) 27% Price Drop

Are Investors Undervaluing Suzhou Basecare Medical Corporation Limited (HKG:2170) By 48%?

Jul 20
Are Investors Undervaluing Suzhou Basecare Medical Corporation Limited (HKG:2170) By 48%?

CEO Compensation Analysis

How has Bo Liang's remuneration changed compared to Suzhou Basecare Medical's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-CN¥250m

Mar 31 2024n/an/a

-CN¥221m

Dec 31 2023CN¥3mCN¥3m

-CN¥192m

Sep 30 2023n/an/a

-CN¥176m

Jun 30 2023n/an/a

-CN¥160m

Mar 31 2023n/an/a

-CN¥146m

Dec 31 2022CN¥3mCN¥3m

-CN¥132m

Sep 30 2022n/an/a

-CN¥133m

Jun 30 2022n/an/a

-CN¥135m

Mar 31 2022n/an/a

-CN¥139m

Dec 31 2021CN¥4mCN¥3m

-CN¥144m

Sep 30 2021n/an/a

-CN¥119m

Jun 30 2021n/an/a

-CN¥106m

Mar 31 2021n/an/a

-CN¥490m

Dec 31 2020CN¥8mCN¥1m

-CN¥874m

Sep 30 2020n/an/a

-CN¥1b

Jun 30 2020n/an/a

-CN¥1b

Mar 31 2020n/an/a

-CN¥822m

Dec 31 2019CN¥732kCN¥602k

-CN¥528m

Compensation vs Market: Bo's total compensation ($USD417.35K) is above average for companies of similar size in the Hong Kong market ($USD231.18K).

Compensation vs Earnings: Bo's compensation has increased whilst the company is unprofitable.

CEO

Bo Liang (43 yo)

14yrs

Tenure

CN¥3,046,000

Compensation

Dr. Bo Liang serves as Executive Director and General Manager at Suzhou Basecare Medical Corporation Limited since December 14, 2010 and serves as its Chairman of the Board since December 14, 2015. Dr. Lia...

Leadership Team

NamePositionTenureCompensationOwnership
Bo Liang
Chairman of the Board & GM14yrsCN¥3.05mno data
Lingyin Kong
CTO & Executive Director10.6yrsCN¥1.40mno data
Ying Yang
Chief Quality Officer6.3yrsCN¥677.00kno data
Lejun Yin
CFO & Joint Company Secretary2.1yrsno datano data
Maoshe Rui
Chief Operating Officer7.5yrsCN¥306.00kno data
Junchao Jiang
Executive Directorless than a yearno datano data
Ming Fai Chung
Joint Company Secretary2.3yrsno datano data

6.3yrs

Average Tenure

43yo

Average Age

Experienced Management: 2170's management team is seasoned and experienced (6.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Bo Liang
Chairman of the Board & GM14yrsCN¥3.05mno data
Lingyin Kong
CTO & Executive Director8.5yrsCN¥1.40mno data
Junchao Jiang
Executive Directorless than a yearno datano data
Xixiong Kang
Independent Non-Executive Director3.9yrsCN¥180.00kno data
Wenbo Xu
Non-Executive Director6.1yrsno datano data
Weipeng Wang
Non-Executive Director8.3yrsno datano data
Yi Lin
Supervisor4.3yrsno datano data
Siu Wing Lam
Independent Non-Executive Director1.4yrsCN¥84.00kno data
Shu Biu Yeung
Independent Non-executive Director1.3yrsCN¥70.00kno data
Yang Ling
Non-executive Director1.3yrsno datano data
Lijuan Shi
Chairwoman of the Supervisory Board1.4yrsno datano data
Qiuping Zong
Supervisor1.4yrsno datano data

2.7yrs

Average Tenure

43yo

Average Age

Experienced Board: 2170's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 16:53
End of Day Share Price 2024/12/24 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Suzhou Basecare Medical Corporation Limited is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jiaying FuChina International Capital Corporation Limited
Shuo SongCitic Securities Co., Ltd.
Mujun ShenCitic Securities Co., Ltd.